Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a
BACKGROUND: Typhoid persists as a major cause of global morbidity. While several licensed vaccines to prevent typhoid are available, they are of only moderate efficacy and unsuitable for use in children less than two years of age. Development of new efficacious vaccines is complicated by the human h...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
Public Library of Science
2016
|
| _version_ | 1797104665997869056 |
|---|---|
| author | Darton, T Jones, C Blohmke, C Waddington, C Zhou, L Peters, A Haworth, K Sie, R Green, C Jeppesen, C Moore, M Thompson, B John, T Kingsley, R Yu, L Voysey, M Hindle, Z Lockhart, S Sztein, M Dougan, G Angus, B Levine, M Pollard, A |
| author_facet | Darton, T Jones, C Blohmke, C Waddington, C Zhou, L Peters, A Haworth, K Sie, R Green, C Jeppesen, C Moore, M Thompson, B John, T Kingsley, R Yu, L Voysey, M Hindle, Z Lockhart, S Sztein, M Dougan, G Angus, B Levine, M Pollard, A |
| author_sort | Darton, T |
| collection | OXFORD |
| description | BACKGROUND: Typhoid persists as a major cause of global morbidity. While several licensed vaccines to prevent typhoid are available, they are of only moderate efficacy and unsuitable for use in children less than two years of age. Development of new efficacious vaccines is complicated by the human host-restriction of Salmonella enterica serovar Typhi (S. Typhi) and lack of clear correlates of protection. In this study, we aimed to evaluate the protective efficacy of a single dose of the oral vaccine candidate, M01ZH09, in susceptible volunteers by direct typhoid challenge. METHODS AND FINDINGS: We performed a randomised, double-blind, placebo-controlled trial in healthy adult participants at a single centre in Oxford (UK). Participants were allocated to receive one dose of double-blinded M01ZH09 or placebo or 3-doses of open-label Ty21a. Twenty-eight days after vaccination, participants were challenged with 104CFU S. Typhi Quailes strain. The efficacy of M01ZH09 compared with placebo (primary outcome) was assessed as the percentage of participants reaching pre-defined endpoints constituting typhoid diagnosis (fever and/or bacteraemia) during the 14 days after challenge. Ninety-nine participants were randomised to receive M01ZH09 (n = 33), placebo (n = 33) or 3-doses of Ty21a (n = 33). After challenge, typhoid was diagnosed in 18/31 (58.1% [95% CI 39.1 to 75.5]) M01ZH09, 20/30 (66.7% [47.2 to 87.2]) placebo, and 13/30 (43.3% [25.5 to 62.6]) Ty21a vaccine recipients. Vaccine efficacy (VE) for one dose of M01ZH09 was 13% [95% CI -29 to 41] and 35% [-5 to 60] for 3-doses of Ty21a. Retrospective multivariable analyses demonstrated that pre-existing anti-Vi antibody significantly reduced susceptibility to infection after challenge; a 1 log increase in anti-Vi IgG resulting in a 71% decrease in the hazard ratio of typhoid diagnosis ([95% CI 30 to 88%], p = 0.006) during the 14 day challenge period. Limitations to the study included the requirement to limit the challenge period prior to treatment to 2 weeks, the intensity of the study procedures and the high challenge dose used resulting in a stringent model. CONCLUSIONS: Despite successfully demonstrating the use of a human challenge study to directly evaluate vaccine efficacy, a single-dose M01ZH09 failed to demonstrate significant protection after challenge with virulent Salmonella Typhi in this model. Anti-Vi antibody detected prior to vaccination played a major role in outcome after challenge. TRIAL REGISTRATION: ClinicalTrials.gov (NCT01405521) and EudraCT (number 2011-000381-35). |
| first_indexed | 2024-03-07T06:36:49Z |
| format | Journal article |
| id | oxford-uuid:f7efda85-ee14-4a20-82b4-7744b6af392c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T06:36:49Z |
| publishDate | 2016 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:f7efda85-ee14-4a20-82b4-7744b6af392c2022-03-27T12:46:33ZUsing a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21aJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f7efda85-ee14-4a20-82b4-7744b6af392cEnglishSymplectic Elements at OxfordPublic Library of Science2016Darton, TJones, CBlohmke, CWaddington, CZhou, LPeters, AHaworth, KSie, RGreen, CJeppesen, CMoore, MThompson, BJohn, TKingsley, RYu, LVoysey, MHindle, ZLockhart, SSztein, MDougan, GAngus, BLevine, MPollard, ABACKGROUND: Typhoid persists as a major cause of global morbidity. While several licensed vaccines to prevent typhoid are available, they are of only moderate efficacy and unsuitable for use in children less than two years of age. Development of new efficacious vaccines is complicated by the human host-restriction of Salmonella enterica serovar Typhi (S. Typhi) and lack of clear correlates of protection. In this study, we aimed to evaluate the protective efficacy of a single dose of the oral vaccine candidate, M01ZH09, in susceptible volunteers by direct typhoid challenge. METHODS AND FINDINGS: We performed a randomised, double-blind, placebo-controlled trial in healthy adult participants at a single centre in Oxford (UK). Participants were allocated to receive one dose of double-blinded M01ZH09 or placebo or 3-doses of open-label Ty21a. Twenty-eight days after vaccination, participants were challenged with 104CFU S. Typhi Quailes strain. The efficacy of M01ZH09 compared with placebo (primary outcome) was assessed as the percentage of participants reaching pre-defined endpoints constituting typhoid diagnosis (fever and/or bacteraemia) during the 14 days after challenge. Ninety-nine participants were randomised to receive M01ZH09 (n = 33), placebo (n = 33) or 3-doses of Ty21a (n = 33). After challenge, typhoid was diagnosed in 18/31 (58.1% [95% CI 39.1 to 75.5]) M01ZH09, 20/30 (66.7% [47.2 to 87.2]) placebo, and 13/30 (43.3% [25.5 to 62.6]) Ty21a vaccine recipients. Vaccine efficacy (VE) for one dose of M01ZH09 was 13% [95% CI -29 to 41] and 35% [-5 to 60] for 3-doses of Ty21a. Retrospective multivariable analyses demonstrated that pre-existing anti-Vi antibody significantly reduced susceptibility to infection after challenge; a 1 log increase in anti-Vi IgG resulting in a 71% decrease in the hazard ratio of typhoid diagnosis ([95% CI 30 to 88%], p = 0.006) during the 14 day challenge period. Limitations to the study included the requirement to limit the challenge period prior to treatment to 2 weeks, the intensity of the study procedures and the high challenge dose used resulting in a stringent model. CONCLUSIONS: Despite successfully demonstrating the use of a human challenge study to directly evaluate vaccine efficacy, a single-dose M01ZH09 failed to demonstrate significant protection after challenge with virulent Salmonella Typhi in this model. Anti-Vi antibody detected prior to vaccination played a major role in outcome after challenge. TRIAL REGISTRATION: ClinicalTrials.gov (NCT01405521) and EudraCT (number 2011-000381-35). |
| spellingShingle | Darton, T Jones, C Blohmke, C Waddington, C Zhou, L Peters, A Haworth, K Sie, R Green, C Jeppesen, C Moore, M Thompson, B John, T Kingsley, R Yu, L Voysey, M Hindle, Z Lockhart, S Sztein, M Dougan, G Angus, B Levine, M Pollard, A Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a |
| title | Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a |
| title_full | Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a |
| title_fullStr | Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a |
| title_full_unstemmed | Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a |
| title_short | Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a |
| title_sort | using a human challenge model of infection to measure vaccine efficacy a randomised controlled trial comparing the typhoid vaccines m01zh09 with placebo and ty21a |
| work_keys_str_mv | AT dartont usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT jonesc usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT blohmkec usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT waddingtonc usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT zhoul usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT petersa usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT haworthk usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT sier usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT greenc usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT jeppesenc usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT moorem usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT thompsonb usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT johnt usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT kingsleyr usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT yul usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT voyseym usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT hindlez usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT lockharts usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT szteinm usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT dougang usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT angusb usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT levinem usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a AT pollarda usingahumanchallengemodelofinfectiontomeasurevaccineefficacyarandomisedcontrolledtrialcomparingthetyphoidvaccinesm01zh09withplaceboandty21a |